Metformin and Adipose Tissue: A Multifaceted Regulator in Metabolism, Inflammation, and Regeneration.

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

• Level A · Stronger Clinical Evidence
• Level B · Emerging clinical evidence with positive signals
• Level C · Early human research exploring benefits
• Level D · Scientific groundwork from lab and animal studies
• Emerging · Emerging topic under active research

Abstract (original English)

Metformin, a first-line treatment for type 2 diabetes mellitus (T2DM), has garnered attention due to its pleiotropic effects beyond glycemic control. In addition to improving insulin sensitivity and inhibiting hepatic gluconeogenesis, metformin modulates inflammation, oxidative stress, and cellular metabolism, particularly within adipose tissue. Adipose tissue is a crucial endocrine organ that plays a central role in metabolic homeostasis and is integral to obesity and T2DM pathogenesis. This review discusses the actions of metformin on white and brown adipose tissues, extracellular matrix remodeling, mature adipocytes, and adipose-derived stem cells. Through both AMP-activated protein kinase-dependent and independent pathways, metformin influences adipogenesis, lipolysis, adipokine secretion, fibrosis, and cellular senescence. We also focus on how the drug concentration influences its biological effects, emphasizing the necessity of physiologically relevant experimental models. These insights deepen our understanding of metformin's therapeutic potential in metabolic and age-related disorders.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.